Clinical trials
CAR T Cell clinical trials
Below are recruiting car t cell clinical trials, each written for real people, not researchers. We’re tracking 697 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05674175RecruitingPhase 1/Phase 2
Test two engineered immune cell treatments for B-cell leukemia
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
Philadelphia, PennsylvaniaAges Up to 29 years - NCT07085559RecruitingEarly Phase 1
Metabolically armed BCMA CAR-T for relapsed plasma cell cancer
This trial tests a new type of CAR-T cell therapy (Meta10-BCMA) that is "metabolically armed" to better fight cancer cells. It's for people with plasma cell cancers that have come back or not responded to multiple prior treatments, and whose cancer cells carry the BCMA protein.
Hefei, AnhuiAges 19–75 - NCT07148791RecruitingPhase 2
CAR-T therapy for relapsed or refractory IgG4-related disease
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
Beijing, Beijing MunicipalityAges 18–75 - NCT05528341RecruitingPhase 1
CAR NK cell treatment trial for solid tumor cancers
This Phase 1 study tests a lab-made immune cell treatment (CAR-NK92 cells) for people with solid tumors that have not responded to earlier treatments. The goal is to see how safe it is and whether it can shrink tumors or help control cancer.
Xinxiang, HenanAges 18–75 - NCT05858684RecruitingEarly Phase 1
CAR-T therapy for hard-to-control lupus
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT03271632RecruitingPhase 1/Phase 2
Multi-CAR T cell therapy for multiple myeloma
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
Shenzhen, GuangdongAges 18–80 - NCT06649227RecruitingPhase 1
CD19 CAR-T cells for hard-to-treat AML
This study tests a new type of immunotherapy (CAR-T cells that target CD19) for adults with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It aims to see if these CAR-T cells are safe and can help control the leukemia.
LilleAges 18 years+ - NCT07432334RecruitingPhase 1
CAR T-cell therapy for hard-to-treat lupus
This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.
HanoiAges 16–55 - NCT06802406Recruiting
Nutrition support for transplant or cell therapy patients
This study tests a program to help patients who are getting a transplant or cell therapy and have trouble getting enough food. It provides nutrition resources to improve their health during treatment.
Stanford, CaliforniaAges 8–80 - NCT07246304RecruitingEarly Phase 1
Cell therapy for DLL3-positive small cell lung cancer
This trial tests a new cell therapy called TC-D101 for people with a type of small cell lung cancer that has DLL3 protein on its surface. It may be an option if standard treatments have stopped working or are not suitable.
Nanjing, JiangsuAges 18–75 - NCT06355739Recruiting
CAR T cells for children with relapsed B-cell leukemia
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
Tianjin, Tianjin MunicipalityAges 3–18 - NCT05620706Recruiting
GPC-3 CAR-T for advanced liver cancer
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
Shenzhen, GuangdongAges 40–70 - NCT05948033RecruitingPhase 1/Phase 2
CD70-targeted CAR-T for relapsed lymphoma with CD70
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT06055439RecruitingPhase 1/Phase 2
CAR T cell therapy for GI cancers
This trial tests a new type of immunotherapy called CAR T cells that target a protein (CDH17) found on certain stomach, colon, and rectal cancers. It's designed for people whose cancer has spread and has been treated before.
Atlanta, GeorgiaAges 18–85 - NCT06429150RecruitingPhase 1/Phase 2
CAR-T therapy for multiple myeloma or plasmacytoma
This trial tests a new type of immunotherapy called CAR-T cells given as part of an early treatment plan for multiple myeloma or plasmacytoma. The goal is to see if this approach can help achieve a deep remission, especially after a stem cell transplant.
Shenzhen, GuangdongAges 18–80 - NCT07220993RecruitingPhase 1
Modified immune cells for aggressive T-cell cancers
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
Houston, TexasAges Up to 75 years - NCT06006741RecruitingPhase 1
CAR-T cell therapy for multiple myeloma patients
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
Shenzhen, GuangdongAges 18–80 - NCT06585345RecruitingPhase 1/Phase 2
CD7 CAR-T for relapsed or refractory acute leukemia
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
Chengdu, SichuanAges 14–65 - NCT05354375RecruitingPhase 1
PSMA-targeted CAR-T cell therapy for resistant prostate cancer
This Phase 1 study tests whether lab-made immune cells (CAR-T) that target PSMA can treat prostate cancer that keeps growing despite hormone treatment. It may help people whose disease no longer responds to standard endocrine (hormone-blocking) therapy.
Xuzhou, JiangsuAges 18–75 - NCT03356782RecruitingPhase 1/Phase 2
CAR T cells for advanced sarcoma
This trial tests a new type of immune cell therapy (4th generation CAR T cells) designed to recognize and attack sarcoma cells. It's for people with advanced or recurrent sarcoma whose tumors have a specific marker.
Shenzhen, GuangdongAges 1–75 - NCT05554939RecruitingPhase 1/Phase 2
CAR-T cells targeting CD19 for relapsed B-cell lymphoma
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06221553RecruitingPhase 1
New CAR T-cell treatment for DIPG brain tumor
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
Bangkok, PathumwanAges 1–18 - NCT06349343RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
WuhanAges 18–70 - NCT07257640RecruitingPhase 1
IL-5 CAR-T therapy for eosinophilic leukemia
This phase 1 trial tests a new treatment called IL-5 CAR-T for patients with eosinophilic leukemia that has not responded to or has returned after standard therapy. It uses your own immune cells that are modified to target and kill cancer cells that have a specific marker called CD125.
Hangzhou, ZhejiangAges 18 years+
Hear when a new CAR T Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car t cell?
- Yes. Clin2 currently lists 697 recruiting car t cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car t cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car t cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.